12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Obeticholic acid: Phase IIa data

Top-line data from the open-label, U.K. Phase IIa OBADIAH trial in patients with bile acid diarrhea showed that once-daily 25 mg obeticholic acid for 15 days was associated with a significant improvement in clinical symptoms and increased levels of FGF19 from baseline. FGF19 is a hormone that directly regulates bile acid synthesis in the liver according to Intercept. Data...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >